Janssen Biotech Inc.
800 Ridgeview Drive
Horsham
Pennsylvania
19044
United States
Tel: 888-227-5624
246 articles about Janssen Biotech Inc.
-
Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications
1/8/2024
Simcha Therapeutics today announced that it has entered into a license and option agreement with Janssen Biotech, Inc. (“Janssen”), a Johnson & Johnson company, where Janssen will work to armor select CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18).
-
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
1/3/2024
Elektrofi, Inc. announced that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.
-
LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
12/26/2023
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate.
-
CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
12/26/2023
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC).
-
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
10/9/2023
Protagonist Therapeutics, Inc. announced that the company will be eligible to receive $60M in milestone payments in the fourth quarter for the advancement of JNJ-2113 into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company, the Company's partner in the development of JNJ-2113.
-
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
8/14/2023
Foundation Medicine Inc., announced that it has received approval from the U.S. Food and Drug Administration for FoundationOne®CDx to be used as a companion diagnostic for Janssen Biotech, Inc. AKEEGA™, which was approved by the FDA for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
-
After initial Phase II data for the oral IL-23 receptor antagonist licensed from Protagonist Therapeutics spooked investors, Janssen provided a fuller readout and advanced the candidate.
-
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
5/2/2023
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.
-
Cellular Biomedicine Group Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma
5/2/2023
Cellular Biomedicine Group Inc. (CBMG or the Company), a clinical-stage biopharmaceutical company focused on discovery and development of innovative cellular therapies for cancer and autoimmune diseases, today announced that the Company has entered into a global collaboration and license agreement with Janssen Biotech, Inc.
-
Biocytogen Announces RenLite® Licensing Agreement with Janssen
3/8/2023
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”).
-
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
3/7/2023
Protagonist Therapeutics, Inc. today announced positive topline results from its collaboration with Janssen Biotech, Inc. in the FRONTIER 1 Phase 2b clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.
-
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
2/9/2023
Roche announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.
-
Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.
-
Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table.
-
BioSpace sat down with Roche Global Head of Neurodegeneration Rachelle Doody, Ph.D. and Alzheimer’s Drug Discovery Foundation Co-founder Howard Fillit, M.D. to discuss the highlights.
-
Mersana unveiled a global collaboration with GSK, which gives GSK the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate XMT-2056.
-
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
-
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
-
Bristol Myers Squibb’s Orencia and Johnson & Johnson’s Remicade improved survival rates for people hospitalized with COVID-19 according to a new report by the National Institutes of Health.
-
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T
4/21/2022
Legend Biotech Corporation today announced the achievement of a $50 million milestone under its collaboration agreement with Janssen Biotech, Inc.